OKYO Pharma Limited (OKYO)

OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

OKYO Pharma Announces Purchase of Shares by Director

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

OKYO Pharma Announces Purchase of Shares by Chairman

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

OKYO Pharma Announces Purchase of Shares by Chairman

Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources

Disney streaming margins and parks business in focus ahead of earnings

OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans

Delta Air Lines earnings resilience supports valuation, Bank of America says